


OIRE SC188
AUG 23 2002
NT & TRADEMARK OFFICE


FIGURE 1

Western Blot of Flk-1/SEAPS Immunoprecipitation with MAb
DC101



AUG 23 2002
U.S. PATENT & TRADEMARK OFFICE
SEARCHED INDEXED SERIALIZED FILED

FIGURE 2A



OIR E
AUG 23 2002
JC189
U.S. PATENT & TRADEMARK OFFICE

FIGURE 2B






FIGURE 3A

MAb (5 μ g/ml)	+	+	+	+	-	-	-	+
VEGF (ng/ml)	80	40	20	10	80	40	20	10



Anti-Ptyr

FIGURE 3B







FIGURE 4

Inhibition of VEGF-Flk-1/fms activation by pre-bound MAb
DC101




Probe: Anti-Ptyr

Assay conditions: P: MAb pre-bound 15'; VEGF 15'
C: Competitive assay; MAb + VEGF 15'

AUG 23 2002
U.S. PATENT & TRADEMARK OFFICE
9815

FIGURE 5




Probe: Anti-PtYr

- 97

O I P E
AUG 23 2002
7 TRADEMARK OFFICE

FIGURE 6 FACS ANALYSIS OF Anti-flik-1 MAb BINDING TO flik-1/fms TRANSFECTED 3T3 CELLS (C441)



O P E
AUG '02 3 2002
9815
U. S. PATENT & TRADEMARK OFFICE

FIGURE 7 SATURATION BINDING OF MAb DC101 TO THE
flk-1/fms RECEPTOR ON THE TRANSFECTED 3T3 CELL LINE C441







FIGURE 8

Immunoprecipitation of phosphorylated Flk-1/fms from
VEGF stimulated Flk-1/fms transfected 3T3 cells




- Antibodies:
- 1) Rat anti-flk-2 IgG_{2a} 2A13
 - 2) Rat anti-flk-1 IgG₁ DC101
 - 3) Rat anti-flk-2 IgG₁ 23H7
 - 4) Rabbit anti-fms polyclonal IM 133



U.S. PATENT AND TRADEMARK OFFICE
SEARCHED INDEXED

FIGURE 9

Sensitivity of VEGF induced phosphorylation of the Flk-1/fms receptor to inhibition by MAb DC101






105-00011

FIGURE 10

Effect of MAb DC101 on CSF-1 induced phosphorylation of the fms receptor

MAb (5 μ g/ml)	-	+	-	-	+	+
CSF-1 (ng/ml)	-	-	20	40	20	40




Probe: Anti-Ptyr



FIGURE 11

Specificity of MAb DC101 neutralization of the activated Flik-1/fms receptor






Figure 12

AUG 23 2002
JC168
ENT & TRADEMARK OFFICE

FIGURE 13

Immunoprecipitation of phosphorylated receptor bands from VEGF stimulated HUVEC cells





FIGURE 14

CONTROL 10% FBS+EC SUPPLEMENT VEGF





Effect of MAb DC101 on VEGF Receptor Forms in the Tumor Cell Lines A431 and 8161





Figure 15

O P E JCT 68
AUG 23 2002
PATENT & TRADEMARK OFFICE

FIGURE 16A

TREATMENT OF GLIOBLASTOMA XENOGRAFTS WITH RAT anti-flik-1 MAb



STATISTICAL ANALYSIS


flik-1 SLOPE = 16.09

p VALUE FOR flik-1 VERSUS flik-2 TUMOR SIZE = 0.0001

O I P E
AUG 23 2002
PATENT & TRADEMARK OFFICE

FIGURE 16B

TREATMENT OF GLIOBLASTOMA
XENOGRAFTS WITH RAT anti-flik-2 MAb



STATISTICAL ANALYSIS

flik-2 SLOPE = 37.39

p VALUE FOR flik-1 VERSUS flik-2 TUMOR SIZE = 0.0001



FIGURE 17

